医学
失调
肠道菌群
恶性肿瘤
卵巢癌
癌变
癌症
微生物群
结直肠癌
不利影响
生物信息学
肿瘤科
内科学
免疫学
生物
作者
Elena Giudice,Vanda Salutari,Caterina Ricci,Camilla Nero,Maria Vittoria Carbone,Viola Ghizzoni,Lucia Musacchio,C. Landolfo,Maria Teresa Perri,Floriana Camarda,Giovanni Scambia,Domenica Lorusso
标识
DOI:10.1016/j.critrevonc.2021.103542
摘要
Ovarian cancer (OC) is the most lethal gynecological malignancy and very little is known about the underlying tumorigenesis mechanisms. For other tumors, like colorectal cancer, a relationship between several opportunistic pathogens and cancer development and progression has been proven. Recent researches also underline a possible correlation between gut microbiota dysbiosis and cancer treatment efficacy and adverse effects. Several studies have also demonstrated a link between abdominal surgery and gut microbiota modifications. In this paper, we aim to review the available evidences of this issue in OC to understand if there is a relationship between gut microbiota modifications and efficacy and adverse effects of cancer therapies, either surgical and medical treatments. Well-designed clinical studies, with a robust translational component, are required to better understand the modulation of gut microbiota during OC treatment. The microbiota/microbiome composition analysis, in the near future, could represent a novel instrument to personalize anticancer therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI